Disc Medicine (NASDAQ:IRON) CEO John Quisel Sells 34,000 Shares

Disc Medicine, Inc. (NASDAQ:IRON) CEO John Quisel sold 34,000 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $70.21, for a total value of $2,387,140.00. Following the transaction, the chief executive officer owned 226,064 shares of the company’s stock, valued at $15,871,953.44. This trade represents a 13.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Disc Medicine Price Performance

IRON opened at $70.45 on Wednesday. The business has a fifty day moving average of $68.76 and a 200 day moving average of $71.34. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.69 billion, a P/E ratio of -10.64 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). As a group, sell-side analysts anticipate that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Institutional Trading of Disc Medicine

Hedge funds have recently modified their holdings of the company. ANTIPODES PARTNERS Ltd bought a new position in shares of Disc Medicine during the 4th quarter worth approximately $33,000. Aster Capital Management DIFC Ltd acquired a new stake in Disc Medicine in the third quarter valued at approximately $38,000. KBC Group NV acquired a new stake in Disc Medicine in the fourth quarter valued at approximately $80,000. Persistent Asset Partners Ltd purchased a new position in Disc Medicine in the fourth quarter worth $141,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Disc Medicine by 36.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after purchasing an additional 490 shares in the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IRON has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Wedbush reissued an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Wells Fargo & Company raised their price objective on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Truist Financial decreased their target price on Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Finally, Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Disc Medicine has a consensus rating of “Moderate Buy” and an average target price of $105.80.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.